Want to see PMVP full AI Analyst Report?
Top Page
PMV Pharmaceuticals
(NASDAQ:PMVP)
Select Model
Select Model
Rating:54Neutral
Price Target:
$1.00
▼(-19.35% Downside)
Action:Reiterated
Date:07/15/26
The score is held back primarily by weak financial performance (no revenue, sizable ongoing losses, and sustained cash burn implying future funding needs). Technicals are a meaningful positive, with the stock above key moving averages and supported by positive momentum indicators. Valuation is difficult to assess due to negative earnings and no dividend yield, while corporate events provide a modest governance-positive tailwind.
Positive Factors
Targeted p53-focused pipeline
A clear scientific focus on restoring/modulating p53 creates a durable specialization in precision oncology. That concentrated expertise can produce differentiated assets, attract partnered funding and trial networks, and increase the chance of targeted approvals or licensing deals over the next 2–6 months and beyond.
Negative Factors
No commercial revenue
Being fully pre-revenue means the company lacks operational cash inflow and must rely on external financing or partnerships to sustain development. This structural absence of revenue limits long-term self-funding, increases dilution risk, and delays visibility into sustainable margins or commercial viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Targeted p53-focused pipeline
A clear scientific focus on restoring/modulating p53 creates a durable specialization in precision oncology. That concentrated expertise can produce differentiated assets, attract partnered funding and trial networks, and increase the chance of targeted approvals or licensing deals over the next 2–6 months and beyond.
Read all positive factors
PMV Pharmaceuticals (PMVP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$59.20M
Dividend YieldN/A
Average Volume (3M)292.35K
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue GrowthN/A
EPS Growth-26.14%
CountryUS
Employees54
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.49
Shares Outstanding53,331,764
10 Day Avg. Volume354,567
30 Day Avg. Volume292,353
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.00Price Target Upside222.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.34
Revenue Forecast (FY)N/A
PMV Pharmaceuticals Business Overview & Revenue Model
Company Description
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a s...
How the Company Makes Money
PMV Pharmaceuticals is a clinical-stage biotechnology company and, as such, it generally does not have recurring product sales from commercialized drugs. Its ability to generate revenue is primarily tied to (a) collaboration or licensing arrangeme...
PMV Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -66.00K | 0.00 | -1.14M | -1.26M | -650.00K | -1.28M |
| EBITDA | -78.19M | -79.78M | -73.67M | -67.70M | -72.68M | -56.54M |
| Net Income | -78.34M | -77.74M | -58.71M | -68.96M | -73.32M | -57.85M |
Balance Sheet | ||||||
| Total Assets | 96.56M | 116.56M | 191.29M | 252.15M | 270.31M | 331.57M |
| Cash, Cash Equivalents and Short-Term Investments | 93.55M | 112.94M | 169.45M | 203.06M | 241.05M | 297.16M |
| Total Debt | 293.00K | 838.00K | 1.19M | 13.29M | 13.98M | 11.19M |
| Total Liabilities | 8.60M | 11.85M | 15.21M | 26.46M | 24.28M | 23.01M |
| Stockholders Equity | 87.97M | 104.71M | 176.08M | 225.69M | 246.03M | 308.56M |
Cash Flow | ||||||
| Free Cash Flow | -75.02M | -73.61M | -51.94M | -56.62M | -71.74M | -47.92M |
| Operating Cash Flow | -74.99M | -73.58M | -51.28M | -55.66M | -63.76M | -46.57M |
| Investing Cash Flow | 62.28M | 70.17M | 53.35M | -50.55M | -1.37M | -143.58M |
| Financing Cash Flow | 495.00K | 505.00K | 313.00K | 35.58M | 958.00K | 2.02M |
PMV Pharmaceuticals Technical Analysis
Negative
1.24
Price Trends
1.20
Negative
1.29
Negative
1.28
Negative
Market Momentum
-0.03
Positive
46.34
Neutral
33.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMVP, the sentiment is Negative. The current price of 1.24 is above the 20-day moving average (MA) of 1.24, above the 50-day MA of 1.20, and below the 200-day MA of 1.28, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 46.34 is Neutral, neither overbought nor oversold. The STOCH value of 33.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PMVP.
PMV Pharmaceuticals Risk Analysis
PMV Pharmaceuticals disclosed 77 risk factors in its most recent earnings report. PMV Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PMV Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $59.20M | -0.74 | -68.98% | ― | ― | -26.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $366.37M | -4.34 | -118.24% | ― | 138.86% | 42.14% | |
50 Neutral | $375.39M | -0.88 | -94.90% | ― | -71.26% | -300.04% | |
47 Neutral | $71.66M | -2.90 | -201.43% | ― | ― | 33.86% | |
41 Neutral | $26.82M | -8.79 | -92.03% | ― | -100.00% | -170.04% |
* Healthcare Sector Average
PMVP
PMV Pharmaceuticals
1.18
-0.27
-18.62%
XFOR
X4 Pharmaceuticals
4.17
2.71
185.62%
ABVC
ABVC BioPharma
1.02
-1.60
-61.07%
PRLD
Prelude Therapeutics
4.68
3.82
444.19%
GANX
Gain Therapeutics
1.78
0.29
19.46%
IMMX
Immix Biopharma
10.06
7.67
320.92%
PMV Pharmaceuticals Corporate Events
Executive/Board ChangesShareholder Meetings
PMV Pharmaceuticals Shareholders Back Directors and Governance Matters
Positive
Jun 5, 2026
On June 4, 2026, PMV Pharmaceuticals held its virtual 2026 Annual Meeting of Stockholders, where shareholders elected David H. Mack, Ph.D., and Laurie Stelzer as Class III directors to serve until the 2029 annual meeting, reinforcing continuity in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.